Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
Karl Matchett

SHOCKING: What astrazeneca could cost london s stock market if it moves to us | Mind Blowing Facts

  • AstraZeneca's CEO, Pascal Soriot, has reportedly held private discussions about moving the pharmaceutical firm's stock market listing from London to the US.
  • The potential move is primarily driven by the CEO's long-standing frustrations with UK regulations, including restrictions on new medicines and pricing structures.
  • Such a shift would represent a significant blow to the London Stock Exchange, as AstraZeneca is currently its largest listed company with a market capitalisation exceeding £161bn.
  • The US is AstraZeneca's largest revenue source, contributing $21.8bn (£15.3bn) of its $54bn (£39bn) total revenue in 2024, highlighting the market's importance to its growth strategy.
  • The company previously abandoned plans for a £450m vaccine hub near Liverpool, citing “timing” and a funding gap, amid ongoing discussions with the UK government regarding pharmaceutical industry support.

IN FULL

Fears over £160bn blow to London’s stock market as AstraZeneca considers listing move to US

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.